Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 6/20 | 0.40 |
| ▸ | CNR1 | P21554 | 5/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833544 | 0.81 | NR5A1 (0.45) | NR5A1LTA4HPLA2G2ATSHRCNR2 | |
| SCHEMBL17463435 | 0.77 | LTA4H (0.47) | NR5A1LTA4HPLA2G2ACNR2CNR1 | |
| SCHEMBL28518816 | 0.76 | PLA2G2A (0.57) | NR5A1PLA2G2ATSHRCNR2CNR1 | |
| SCHEMBL28531920 | 0.76 | PLA2G2A (0.57) | NR5A1PLA2G2ATSHRCNR2CNR1 | |
| SCHEMBL28531863 | 0.76 | PLA2G2A (0.57) | NR5A1PLA2G2ATSHRCNR2CNR1 | |
| SCHEMBL38663395 | 0.75 | NR5A1 (0.59) | NR5A1LTA4HTSHRCNR2BLM | |
| SCHEMBL21486432 | 0.75 | NR5A1 (0.64) | NR5A1LTA4HTSHRCNR2 | |
| SCHEMBL168063 | 0.75 | NR5A1 (0.62) | NR5A1LTA4HPLA2G2ACNR2CNR1 | |
| SCHEMBL8889344 | 0.73 | NR5A1 (0.66) | NR5A1LTA4HPLA2G2ACNR2CNR1 | |
| SCHEMBL6816991 | 0.73 | NR5A1 (0.66) | NR5A1LTA4HPLA2G2ACNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303507-A1 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303507-A1 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | CNR2, CNR1, GPR18 | NR5A1 4541/4885LTA4H 4220/4885PLA2G2A 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.